SinoMab BioScience publishes 2025 annual report

• SinoMab BioScience annual report for year ended Dec. 31, 2025, highlighted SM17 Phase 1b topline data in China for moderate-to-severe atopic dermatitis, with 91.7% of high-dose patients achieving NRS-4 pruritus relief.
• Pipeline expansion progressed with SM17 inflammatory bowel disease IND accepted by China drug regulator on Dec. 11, 2025, then cleared in February 2026.
• Clinical execution shifted toward broader development, with SM17 subcutaneous bridging study dosing started in October 2025, then follow-up for 30 healthy subjects completed in February 2026.
• Strategic focus moved away from rheumatoid arthritis registration for SM03 (Suciraslimab), with BLA voluntarily withdrawn on July 14, 2025, as development pivoted toward systemic lupus erythematosus.
• Manufacturing strategy tilted to an asset-light model, with Haikou production-base lease termination agreed post period, while Suzhou campus secured real estate ownership certificate in March 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260427-12124901), on April 27, 2026, and is solely responsible for the information contained therein.